Top-selling COVID-19 drug Paxlovid could see sales decrease from 2023

22 July 2022

Although many pharmaceutical companies have launched therapeutic drugs for COVID-19, Pfizer’s (NYSE: PFE) Paxlovid (nirmatrelvir and ritonavir tablets) takes the top spot as market leader. The drug has expected peak sales of $30.7 billion in 2022 and total generated sales of $81 billion between 2021 and 2028, according to data and analytics company GlobalData.

Paxlovid is an oral small molecule antiviral combination of nirmatrelvir and ritonavir, that halts viral replication preventing the disease from becoming severe and resulting in hospitalization. Paxlovid sales are followed by Regeneron’s (Nasdaq: REGN) Regen-Cov (casirivimab and imdevimab), Gilead Sciences’ (Nasdaq: GILD) Veklury (remdesivir) and Merck & Co’s (NYSE: MRK) Lagevrio (molnupiravir).

GlobalData’s latest report, ‘ Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H1 2022’, reveals that the peak in sales is likely due to the drug receiving Emergency Use Authorizations (EUAs) across geographies including the USA Japan, China, and South Korea, and being approved in geographies including the UK, the European Union, Canada, and New Zealand.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK